ArticleAntimicrobial agents and chemotherapy2026
Population pharmacokinetic model and dosing nomogram for daptomycin in adult patients with serious Gram-positive infections: emphasizing the role of loading doses and renal function-based adjustment.
Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Current recommendations for daptomycin dosing are based on body weight. However, it can be hypothesized that dosing based on renal function may improve the attainment of recommended pharmacokinetic (PK)/pharmacodynamic (PD) targets. The aim of this study was to develop a population pharmacokinetic model of daptomycin and propose an individualized dosing strategy to optimize target attainment. Therapeutic drug monitoring data from adult patients treated with daptomycin at a single center between 2022 and 2025 were analyzed using a nonlinear mixed-effects modeling. Monte Carlo simulations were then employed to identify the optimal dosing strategy that maximizes the probability of attaining the PK/PD target. A total of 143 daptomycin serum concentrations from 31 patients were included in the analysis. Estimated glomerular filtration rate (eGFR) was identified as the most predictive covariate for daptomycin pharmacokinetics. In a patient with an eGFR of 90 mL/min, the estimated volume of distribution and clearance of daptomycin were 11.47 L and 0.69 L/h, respectively. An eGFR-guided dosing nomogram was proposed, and simulation results demonstrated that this approach outperformed conventional weight-based dosing in achieving the PK/PD target. These findings support the use of an initial loading dose and individualized maintenance dosing based on eGFR to improve the efficacy and safety of daptomycin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.